Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 8/20 | 0.39 |
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251284 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TSHRJAK3BTKJAK1 | |
| SCHEMBL5121118 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TSHRJAK3BTKJAK1 | |
| SCHEMBL18616042 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TSHRJAK3BTKJAK1 | |
| SCHEMBL490369 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TSHRLMNAJAK3BTK | |
| SCHEMBL22138107 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TSHRLMNA | |
| SCHEMBL23683510 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TSHRLMNAJAK3BTK | |
| SCHEMBL18585913 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TSHRLMNAJAK3BTK | |
| SCHEMBL22138108 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TSHRLMNA | |
| SCHEMBL20656791 | 0.82 | SMN1; SMN2 (0.50) | ALDH1A1JAK3JAK1 | |
| SCHEMBL10292166 | 0.80 | ALDH1A1 (0.49) | ALDH1A1TSHRLMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | disclosed |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| WO-2017134588-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, JAK1 | ALDH1A1 594/4885TSHR 2497/4885LMNA 2570/4885 |
| US-10435409-B2 | Process for the preparation of ibrutinib | BTK, SYK, JAK1 | ALDH1A1 534/4885TSHR 2607/4885LMNA 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.